News

15 March 2021

By Andreas Weber, Group Chief Executive Officer (CEO)

EvidentIQ group to launch new eCOA and eFeasibility offerings combining scientific services with a comprehensive software suite usable on any device.

HAMBURG, Germany,  March 15th, 2021 – Data science group EvidentIQ with operations in Germany, France and the US, announced today the launch of their next generation eCOA and eFeasibility solutions for CROs and study sponsors. In a rapidly growing market, the EvidentIQ offering stands out as it combines a comprehensive tech stack with proven scientific services to support pharmaceutical companies, CROs and sponsor teams throughout the feasibility and clinical outcome data collection phase of their clinical trials.

With its comprehensive eCOA solution, the new data science group, which has only recently been built by merging long-established providers XClinical, Carenity and Fortress Medical, has set out to fuse data science services and a scalable software platform. EvidentIQ customers benefit from an end-to-end eCOA package allowing to collect any patient / clinician / observer reported outcome data in a streamlined, compliant and efficient way. The solution can be used stand-alone or fully integrated into existing eClinical technologies, such as EDC systems. The EvidentIQ eCOA offering supports a bring-your-own-device (BYOD) policy and works on any iOS/Android phone.

Combining a software platform with scientific services

EvidentIQ’s combined offering of a platform with a scientific service offering attached to it empowers LifeScience professionals to conduct virtual and hybrid clinical trials. Unique eFeasibility solutions help optimize clinical trials and accelerate patient recruitment with a patient-centric approach.

EvidentIQ relies on Data Science and robust technologies to custom the design of clinical trials optimizing Product Profiles, Endpoints, Protocols, ICFs, and eCRFs. The package facilitates a complete digitalized patient enrollment journey for clinical trials from Multi-channel Pre-screening over eConsent Management to the Clinical Data Capture in the EDC.  

Steady Market Growth for eCOA

Andreas Weber, CEO of EvidentIQ, points out the substantial market growth for Electronic Clinical Outcome Assessment:

“Most market analyses expect a CAGR of more than 15% for the eCOA market until 2027, and a global market volume of approximately 2.5 billion USD by then.”

When asked for the main drivers causing this growth Weber sees multiple developments besides the global Covid-19 pandemic.

“Keep in mind there is a high demand for clinical trials in emerging markets and consistently high R&D spendings in the pharmaceutical industry. Besides FDA and EMA are taking a tougher stance on COA data collection meeting regulatory quality guidelines.”

“Our new eCOA offering demonstrates perfectly how we create value for our customers and in doing so build a unique market position for our group. We empower life science companies of all sizes to transition from outdated, error-prone paper-based processes to digital data capture and data processing.”

Contact us for more information on eCOA by EvidentIQ

Hello, I'm Andreas Weber, Group Chief Executive Officer (CEO)

I strongly believe we have a unique chance to build an innovative new group of companies leveraging the individual strengths of XClinical, Fortress Medical Systems, Carenity, and the synergies across the three entities.

Clinical Trial Backgrounds, News

12 April 2021

How to Select CTMS that will Positively Impact the Quality of your Study

Read more

News

27 March 2019

What is CDISC and Why Does It Matter?

Read more

Clinical Trial Backgrounds, News

28 May 2019

Decoding the Alphabet Soup: A Guide to Clinical Research Acronyms

Read more
Copyright © XClinical. All Rights Reserved.
Home